Swiss pharma major Novartis (NOVN: VX) has announced a swap of clinical assets for equity with UK-based specialty biopharmaceutical company bio Mereo BioPharma Group, which focuses on rare and specialist disease areas.
The deal involves compounds in areas of unmet medical need including BPS-804, to improve bone density in brittle bone syndrome, BCT-197 for acute exacerbations in chronic obstructive pulmonary disease (COPD), and BGS-649 for obese men with hypogonadotrophic hypogonadism to normalize testosterone levels. Under the terms of the agreement, Novartis will have an equity stake in Mereo and will share in the success of the development of these compounds, including a share on milestones and royalties on future commercial sales.
David Epstein, head of Novartis Pharmaceuticals, said: “We are pleased that through this deal with Mereo we have found a way to work together to bring these valued innovations to patients.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze